Audrey Wang was so burned out from her job in high-end estate management that she broke out in hives that lasted six years.

Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria Approval ...

(BPT) – If you’ve had hives, you know how challenging they can be. But you may not know that there is more than one type of hives, or urticaria, and that treatments are available. A brief episode of ...

Dupixent has gained EU approval as the first targeted therapy in more than ten years for chronic spontaneous urticaria, ...

Patients with chronic spontaneous urticaria (CSU) experienced improved quality of life and sleep when symptoms were mitigated ...

—A recent study found that more than half of people with chronic urticaria experience a significant impact on their work. Chronic urticaria (CU) is a common skin condition characterized by the ...

The approval marks the first for a targeted treatment in chronic spontaneous urticaria in Europe in over a decade.

Adults with moderate to severe chronic spontaneous urticaria who received once-daily 75 mg povorcitinib for 12 weeks had a ...

If you're being treated for hives, your physician will want to hear what you think about your treatment. Is it working? Are your symptoms improving, staying the same, or getting worse? You may be ...

Among adults with chronic spontaneous urticaria inadequately controlled by H1 antihistamine treatment, remibrutinib improved ...

Approval based on phase 3 studies showing Dupixent significantly reduced itch and hives at 24 weeks compared to placeboIn the EU, there are approximately 270,000 adults and adolescents aged 12 years ...